Use in Specific Populations
LuciCeno provides important guidance for healthcare professionals when prescribing the medication to patient populations whose safety profile, drug metabolism, or therapeutic response may differ from the general population. These considerations help ensure safe, individualized treatment.
Pregnancy
- Risk Considerations:
It is currently unknown whether LuciCeno is safe during pregnancy. Available data are insufficient to fully assess potential risks to the developing fetus. - Clinical Guidance:
Healthcare providers should carefully weigh the benefits and risks for pregnant patients. Enrollment in a pregnancy exposure registry may be recommended if available.
Lactation (Breastfeeding)
- Risk Summary:
It is not known whether LuciCeno or its metabolites pass into human breast milk, or whether they may affect a breastfed infant or milk production. - Clinical Considerations:
Providers may recommend avoiding breastfeeding during treatment or adjusting feeding schedules to minimize potential infant exposure.
Females and Males of Reproductive Potential
This subsection applies when reproductive risks require specific guidance:
- Pregnancy testing may be recommended before and during treatment.
- Effective contraception should be used during therapy and for a period after stopping treatment.
- LuciCeno may reduce the effectiveness of hormonal contraceptives, so non-hormonal methods may be required.
- Information on potential effects on fertility may be based on animal or human data.
Pediatric Use
- The safety and effectiveness of LuciCeno have not been established in pediatric patients.
- Use in children should only occur if specifically advised by a specialist, with careful monitoring.
Geriatric Use (Age 65 and Older)
- Clinical studies may include limited numbers of older adults.
- Age-related changes in kidney or liver function may affect how the drug is processed.
- Dose adjustments and closer monitoring may be necessary in elderly patients.
Patients with Renal Impairment
- Reduced kidney function can affect drug elimination.
- Dosing recommendations vary depending on the severity of renal impairment.
- LuciCeno is not recommended for patients with end-stage renal disease (ESRD).
Patients with Hepatic Impairment
- Liver dysfunction can alter drug metabolism.
- Dosing adjustments or increased monitoring may be required for mild to moderate impairment.
- LuciCeno should not be used in patients with severe liver impairment (Child-Pugh Class C).
Contraindications: Who Should Not Take LuciCeno
Do not take LuciCeno if you have:
- A known allergy to cenobamate or any of its ingredients
- Familial short QT syndrome (a genetic heart rhythm disorder)
- Severe liver disease (Child-Pugh Class C)
- End-stage kidney disease (CKD stage 5; GFR < 15 mL/min)
Use with Caution: Talk to Your Doctor If You Have
- A history of depression, mood changes, or suicidal thoughts
- Any degree of liver or kidney disease
- Blood cell disorders
- A history of severe drug-related allergic reactions (especially those involving rash or organ involvement)
Other Important Safety Considerations
- Pregnancy: Safety is not established; alternative contraception may be required.
- Drug Interactions: LuciCeno interacts with many medications. Always disclose all prescriptions, OTC drugs, supplements, and vitamins.
- Alcohol: Avoid alcohol while taking LuciCeno, as it may increase side effects and health risks.
